Pre-Open Stock Movers 07/26: (TYME) (MSTR) (FLOW) Higher; (ATIP) (ITRM) (TNXP) Lower (more...)
Get Alerts TYME Hot Sheet
Join SI Premium – FREE
Pre-Open Stock Movers:
Tyme Technologies, Inc. (NASDAQ: TYME) 54.6% HIGHER; announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Companys metabolomic technology platform. The patent, U.S. Patent No. 11,058,638, involves a targeted delivery of therapeutics to cancer cells.
ATI Physical Therapy (NYSE: ATIP) 41.3% LOWER; reported Q2 revenue of $164 million versus the consensus estimate of $175.37 million. For full year 2021, ATI is now projecting revenue to be in the range of $640 million to $670 million and Adjusted EBITDA to be in the range of $60 million to $70 million, down from $731 million and $119 million, respectively. ATI does not intend to provide revenue guidance as a future guidance metric.
Iterum Therapeutics plc (Nasdaq: ITRM) 40% LOWER; announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) on July 23, 2021. The CRL provided that the FDA has completed its review of the NDA and has determined that it cannot approve the NDA in its present form.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) 35.7% LOWER; decided to stop enrollment in the Phase 3 RALLY study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia following an unblinded, pre-planned interim analysis by the Independent Data Monitoring Committee (IDMC) of the RALLY study. Based on interim analysis results of the first 50% (n=337) enrolled participants, the IDMC recommended stopping the trial for futility as TNX-102 SL is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall change from baseline in daily diary pain severity scores between those treated with TNX-102 SL 5.6 mg (2x 2.8 mg tablets) and those receiving placebo. Tonix remains blinded to the detailed interim analysis results and only received the recommendation made by the IDMC. Preliminary blinded safety data from these participants did not reveal any new safety signals, and the decision to discontinue enrolling new participants is not related to safety. The Company intends to continue studying those participants currently enrolled until completion and then proceed with a full analysis of the unblinded data, with the topline results expected to be reported in the fourth quarter of 2021, to determine the next steps in this program.
New Oriental Education & Technology Group Inc. (NYSE: EDU) 25% LOWER; continues lower on reports last week China is considering taking the company's private
TAL Education Group (NYSE: TAL) 25% LOWER; continues lower on reports last week China is considering taking the company's private
On Sunday, Denali Therapeutics Inc. (NASDAQ: DNLI) 20% LOWER; announced additional positive interim data from a Phase 1/2 study evaluating ETV:IDS (DNL310), an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (CNS) and peripheral manifestations of Hunter syndrome (MPS II). The interim results being presented today at MPS 2021, the 16th International Symposium on MPS and Related Diseases, include safety data up to Weeks 43 and 25 from Cohorts A and B, respectively, 6-month biomarker data from Cohort A and up to 3-month biomarker data from Cohort B. Denali Management will host a webinar today for analysts and investors beginning at approximately 11:30 a.m. Eastern Time.
Riot Blockchain, Inc. (NASDAQ: RIOT) 14% HIGHER; gains on Bitcoin rally
Marathon Digital (NASDAQ: MARA) 13% HIGHER; gains on Bitcoin rally
Microstrategy, Inc. (NASDAQ: MSTR) 13% HIGHER; gains on Bitcoin rally
SPX FLOW, Inc. (NYSE: FLOW) 12.4% HIGHER; announced that its Board of Directors has authorized a review of strategic alternatives, including a possible sale or merger of the Company and the continued execution of the Company's standalone strategy. Previously, the Company announced that its Board of Directors had received and rejected an unsolicited, conditional, non-binding proposal from Ingersoll Rand Inc. (NYSE: IR) to acquire all outstanding shares of SPX FLOW common stock for $85.00 per share. This followed a similar unsolicited proposal from Ingersoll Rand for $81.50 per share.
Tencent Music Entertainment Group (NYSE: TME) 9.3% HIGHER; On Saturday, The State Administration for Market Regulation ordered Tencent to give up its exclusive music licensing rights.
Aon plc (NYSE: AON) 6.2% HIGHER; Aon plc (NYSE: AON) and Willis Towers Watson (NASDAQ: WLTW) announced today that the firms have agreed to terminate their business combination agreement and end litigation with the U.S. Department of Justice (DOJ). The proposed combination was first announced on March 9, 2020.
Coinbase Global, Inc. (NASDAQ: COIN) 5.9% HIGHER; gains on Bitcoin rally
Hasbro (NASDAQ: HAS) 5.5% HIGHER; reported Q2 EPS of $1.05, $0.57 better than the analyst estimate of $0.48. Revenue for the quarter came in at $1.32 billion versus the consensus estimate of $1.17 billion.
Willis Towers Watson (NASDAQ: WLTW) 5.5% LOWER; Aon plc (NYSE: AON) and Willis Towers Watson (NASDAQ: WLTW) announced today that the firms have agreed to terminate their business combination agreement and end litigation with the U.S. Department of Justice (DOJ). The proposed combination was first announced on March 9, 2020.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mobix Labs (MOBX) Secures $100M Committed Equity Facility
- Engine Nominates Two Highly Qualified Candidates for Election to MRC Global’s (MRC) Board
- Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Bitcoin, Pre Market Movers, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!